On October 2, 2018 Medigene AG (FSE: MDG1, Prime Standard, SDAX) reported its participation at the following upcoming investor and scientific conferences (Press release, MediGene, OCT 2, 2018, View Source [SID1234529709]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper)
Date: 30 September – 03 October 2018
Location: New York, USA

European Society of Gene and Cell Therapy (ESGCT) Annual Congress
Date: 16 – 19 October 2018
Location: Lausanne, Switzerland

ESMO – European Society for Medical Oncology Congress
Date: 19 – 23 October 2018
Location: Munich, Germany

BTIG Healthcare Conference
Date: 25 October 2018
Location: New York, USA

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.